MINNEAPOLIS,
Jan. 5,
2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced Matthew F.
McManus has been appointed President, Diagnostics and
Genomics Segment, effective January 8,
2024. Dr. McManus succeeds Kim
Kelderman, who will become Bio-Techne's Chief Executive
Officer effective February 1,
2024.
Dr. McManus has over two decades of experience as
a senior life sciences leader, most recently serving as Executive
Vice President and Chief Operating Officer for Azenta, where he was
responsible for Life Sciences Products, Services, and all
commercial operations of the business. Previously, Dr. McManus was
Senior Vice President and General Manager of Bio-Techne's Molecular
Diagnostics Division following its acquisition of Asuragen, where
Dr. McManus served as President and CEO. Dr. McManus currently
serves as the Chairman of the Board of Directors for ANSA, a
company commercializing disruptive capabilities in gene synthesis
and cell & gene therapy markets. Dr. McManus received his M.D.
and Ph.D. from the University of
Pennsylvania School of Medicine, his MBA from Boston College, and his B.A. in Economics from
College of the Holy Cross.
"I am excited for Matt's return to Bio-Techne,"
said Kim Kelderman, Bio-Techne's
Chief Operating Officer and in-coming Chief Executive Officer.
"Matt's successful prior leadership of Bio-Techne's Molecular
Diagnostics Division, combined with his breadth of life science
experience and knowledge make him the perfect fit for this role.
Matt is the ideal candidate to take the Diagnostics and Genomics
Segment through its next phase of growth."
About Bio-Techne Corporation (NASDAQ:TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-appointment-of-matthew-f-mcmanus-as-president-diagnostics-and-genomics-segment-302026966.html
SOURCE Bio-Techne Corporation